GET DAILY SIGNALSPraxis Precision Medicines (PRAX): Exploring the Path to the $650 Analyst Target
Key Takeaways
- The central $650 stock price target represents the arithmetic mean of roughly 20 verified analyst price targets drawn from firm- and analyst-attributed reports.
- Individual targets range widely from about $162 to $1,201, highlighting sharply divided opinions on the pipeline's probability of success.
- From the latest close of $333.09, reaching $650 would require a gain of roughly 95% — a substantial move.
- Bullish support centers on the multi-billion-dollar ulixacaltamide opportunity in essential tremor and a reported cash runway near $1.4 billion.
- The primary risk remains clinical execution, as a mid-2026 vormatrigine trial miss and subsequent POWER2 pause pushed some targets lower.
- For additional context, explore the Major News, Today's Price Move, Forecast, and Earnings pages for this ticker.
Understanding the Analyst Consensus
The $650 central target is a calculated mean rather than an official consensus figure, based on roughly 20 current, attributable price targets. Dispersion stands out as extreme, with the low end near $162 from a cautious Wedbush view and highs reaching $1,201 at H.C. Wainwright and $1,200 at Piper Sandler. In between, firms split into camps. Optimists including BTIG at $826, Guggenheim at $800, LifeSci Capital at $754, UBS at $706, J.P. Morgan at $700, and Raymond James at $945 focus on ulixacaltamide's commercial potential. Moderates such as Needham at $582, Goldman Sachs at $575, Jefferies at $550, Baird at $514, TD Cowen at $510, and RBC Capital at $462 apply meaningful execution and binary-risk discounts. Wells Fargo holds the most cautious major-bank target at $362. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Ratings lean heavily bullish, with approximately 18 Buy, 1 Hold, and 1 Sell in recent counts, yet the wide range shows the mean is simply a statistical midpoint rather than a firm forecast. It serves best as a broad indicator of expected upside.
Current Market Position and Required Upside
With shares at $333.09, PRAX trades toward the lower half of its 52-week range of roughly $160 to $393 and well below the $650 central target. The needed upside of about 95% represents a very large move that would require a meaningful re-rating rather than incremental progress.
The path depends on clinical and regulatory milestones. Bullish cases center on ulixacaltamide's potential to become a blockbuster in essential tremor, a large and underserved indication, with launch expectations focused around 2028. The counterweight is vormatrigine, where the POWER1 miss and POWER2 pause in mid-2026 reset some targets downward and underscored binary risk in neuroscience drug development.
Factors Supporting a Move Toward the Target
- Pipeline optionality: ulixacaltamide's multi-billion-dollar revenue potential in essential tremor forms the core bull thesis.
- Balance sheet strength: a cash runway of roughly $1.4 billion, cited by TD Cowen, reduces near-term dilution risk.
- Analyst revision trend: the average target has risen substantially over the past year as positive ulixacaltamide data outweighed the vormatrigine setback.
- Unmet need: CNS disorders in its focus areas feature large patient populations and limited approved therapies.
Risks That Could Prevent Reaching the Target
- Clinical binary risk: further trial setbacks, as already seen with vormatrigine, could compress the valuation quickly.
- Regulatory and launch execution: FDA approval and commercial uptake are not assured, and timelines can slip.
- Cash burn: the company remains unprofitable, with projected annual non-GAAP EPS losses in the double digits per share.
- Valuation concentration: with a market capitalization in the multi-billion-dollar range against minimal revenue, the stock is highly sensitive to sentiment shifts.
Technical Levels and Market Structure
PRAX's long-term structure shows a 52-week range from about $160 to $393, placing the $650 target well above even the prior cycle high. A decisive move toward the target would first require a sustained breakout above the $393 area, a meaningful resistance level from the prior high. On the downside, the low-to-mid $200s represented recent support before the November earnings-driven advance, while the $160 zone marks the cycle low. The roughly 95% upside to $650 would require not just a breakout but a re-rating well beyond any level the stock has previously established. From what I see, monitoring these levels closely helps frame the magnitude of the move.
Time Horizon and Key Items to Monitor
Analyst price targets typically reflect a research horizon of approximately 12 months, though individual firms apply their own assumptions and some frames extend to launch milestones. Key items to watch include ulixacaltamide trial readouts and regulatory interactions, vormatrigine program updates, quarterly earnings and cash-burn figures, analyst target revisions, and any financing activity. Given the binary nature of the pipeline, single data events can drive outsized moves in either direction.
Using AI Tools for Ongoing Monitoring
In my own research, I often rely on Tickeron’s AI Daily Buy/Sell Signals to track momentum shifts in volatile, news-sensitive names. The tool applies artificial intelligence to monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on technical behavior and changing market conditions. This approach helps spot emerging trends and manage positions more efficiently alongside fundamental analysis. Explore the AI Daily Buy/Sell Signals to see how automated monitoring might complement your process.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PRAX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for PRAX turned positive on October 20, 2026. Looking at past instances where PRAX's MACD turned positive, the stock continued to rise in 40 of 43 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on PRAX as a result. In 85 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.
PRAX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +26.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRAX advanced for three days, in 257 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 54 of 63 cases where PRAX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.
The 50-day moving average for PRAX moved below the 200-day moving average on October 22, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
PRAX broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PRAX entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.780) is normal, around the industry mean (3.498). P/E Ratio (-21.421) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. PRAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 86 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement